ClinicalTrials.gg
Active, not recruitingNCT06243458(MDS)Updated May 22, 2025

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

A Phase 2 interventional study of RVU120 (SEL120) in Low Risk Myelodysplastic Syndromes, sponsored by GCP-Service International West GmbH. Active, not recruiting at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-22.

Sponsored by GCP-Service International West GmbH · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 134 studies in Myelodysplastic Syndromes with a site in Italy — 18 open to participants now, 34 under way, 12 of them phase 3. Myelodysplastic Syndromes · Italy.

Enrollment
90th of 115
41 · median 129
Started
2024
with 2 others
Phase 2
38 of 134
4 open now
Primary completion
2026-05
later than 10 of 33 live
Registered
124th of 134
by date

Among the 134 studies in Myelodysplastic Syndromes with a site in Italy, this one is the 90th largest by enrollment of the 115 interventional ones that give a count, is one of 3 that started in 2024, is one of 38 in phase 2, reaches primary completion later than 10 of the 33 other live ones, and was the 124th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

18 of the 134 studies in Myelodysplastic Syndromes with a site in Italy are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Myelodysplastic Syndromes with a site in Italy, or all of them as a file.
02

Study summary

This study will evaluate orally administered RVU120, a novel small molecule Cyclin-dependent Kinase (CDK) 8/19 inhibitor, in terms of erythroid hematologic improvement (HI-E) and safety in participants with lower-risk myelodysplastic syndrome (MDS). Responding patients are eligible to continue treatment until loss of response/disease progression.

03

Conditions studied

  • Low Risk Myelodysplastic Syndromes

Keywords

  • CDK8/19 Inhibitor
  • RVU120 (SEL120)
  • Clinical Trial, Phase II
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written provided prior to any study-related procedure
  2. Age ≥18 years
  3. Diagnosis of de novo myelodysplastic neoplasms (MDS) according to World Health Organization (WHO) 2022 criteria.

    Diagnosis will be confirmed during screening assessment.

  4. Very low, low or intermediate risk disease MDS with up to 3.5 points according to International Prognostic Scoring System Score Revised (IPSS-R) classification (to be confirmed during screening assessment).

    Patients with del(5q) and max. one further abnormality (excluding monosomy 7, del(7q), TP53mut) are eligible.

  5. Symptomatic anemia: Symptomatic anemia (all non transfusion dependent (NTD), low transfusion burden (LTB), or high transfusion burden (HTB)) has to be documented in the 16 weeks baseline period ending on the day of inclusion.

    Patients should be registered only if it is expected at time of registration that

    • a valid and complete (at least five measurements in the period of 16 weeks before the first dose of IMP) and transfusion history will be available at inclusion AND
    • the Hb Mean over the baseline period will be less than 10 g/dL OR three or more red blood cell (RBC)-transfusions will have been given during the baseline period documenting transfusion dependence.
  6. No available option of an approved MDS therapy according to decision of the treating physician and based on the following:

    Patients must be

    • ESA exposed (and or intolerant) or ESA naïve and serum erythropoietin level >200 U/L AND/OR
    • Luspatercept exposed (and refractory or intolerant) or luspatercept naïve and not eligible for treatment (e.g. not approved) AND/OR
    • Lenalidomide exposed (and refractory or intolerant) or lenalidomide naïve and not eligible for treatment (e.g. due to non-presence of del(5q))
  7. (ECOG) performance score of 0-2
  8. Patients must have been off anti-cancer treatment for 2 weeks or 5 half-lives, whichever is longer
  9. Clinical laboratory parameters as follows:

    • Peripheral white blood cell (WBC) count, no upper or lower limit at screening, but must be \<10 x 109/L prior to first dose of study drug
    • count >25,000/μL
    • Serum albumin ≥ 30 g/L (3.0 g/dL)
    • Normal coagulation (elevated (INR), prothrombin time or activated partial thromboplastin time (APTT) \<1.3 x acceptable)
    • (AST) and alanine aminotransferase (ALT) ≤3 x the upper limit of normal (ULN)
    • Total ≤1.5 x ULN
    • ≥60 mL/min
    • Urine protein \< 2+ (as measured by dipstick) or ≤1000 mg/24 hours urine
  10. Adequate cardiac function confirmed by (LVEF) ≥40% as per echocardiography or MUGA (Multiple Gated Acquisition) scan
  11. For females of (FCBP), a negative serum pregnancy test must be confirmed before enrolment. FCBP must commit to use of highly effective method of during study participation and until 28 weeks (6.5 months) after the last dose of study drug. Females must also refrain from donating blood or egg (ovum) during the same time-period.
  12. For males, an effective barrier method of contraception must be used during study participation until 28 weeks (6.5 months) after the last dose of study drug, if the patient is sexually active with a FCBP. Males must also refrain from donating blood or sperm during the same time-period.
  13. Investigator considers the patient to be suitable for participation in the clinical study by assessing that they:

    • Understand the requirements of the clinical study and can give informed consent.
    • Can comply with study medication dosing requirements and all study-related procedures and evaluations; and
    • Are not considered to be potentially unreliable and/or not cooperative
  14. Has received all Coronavirus disease-19 (COVID-19) vaccinations per relevant national guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Inability to swallow and retain oral medications.
  2. Patient does not accept bone marrow sampling during screening and after the treatment.
  3. Prior treatment with azacitidine (injectable or oral) or decitabine.
  4. The patient medically requires treatment with the following drugs that are forbidden during the trial or was exposed to one of these 14 days before the first dose of the IMP:

    • Erythropoiesis stimulating agent (ESA) or luspatercept
    • Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF)
    • Lenalidomide
    • Another drug or device, or approved therapy for investigational use
  5. Iron chelation therapy NOTE: if therapy was initiated 56 days or more prior to the first dose of the IMP, patient can be included. Recently initiated iron chelation [\< 56 days prior to registration] might influence interpretation of hematological response after start of trial medication.
  6. Previous treatment with CDK8-targeted therapy(s).
  7. Active central nervous system (CNS) involvement.
  8. Patients who have undergone major surgery within 28 days prior to first dose of study drug.
  9. Evidence of ongoing and uncontrolled systemic bacterial, fungal, or viral infection and acute inflammatory conditions (including pancreatitis)
  10. Hematopoietic stem cell transplant within 120 days prior to first dose of study drug.
  11. Active Grade 2-4 acute (GVHD), active moderate-to-severe chronic GVHD, or requirement for systemic medications for GVHD.
  12. Known seropositivity or history of active viral infection with (HIV).
  13. Ongoing significant liver disease such as cirrhosis, drug-induced liver injury, active hepatitis or chronic persistent and/or C:

    • Positive serologic or polymerase chain reaction (PCR) test results for acute or chronic Hepatitis B virus (HBV) infection. Patients whose HBV infection status cannot be determined by serologic test results must be negative for HBV by PCR to be eligible for study participation.
    • Acute or chronic virus (HCV) infection. Patients who are positive for HCV antibody must be negative for HCV by PCR to be eligible for study participation
  14. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RVU120 (e.g. active inflammatory bowel disease, ulcerative disease, malabsorption syndrome, short bowel syndrome, uncontrolled nausea, vomiting or diarrhea).
  15. Ongoing drug-induced pneumonitis.
  16. Concurrent participation in another investigational clinical trial.
  17. Taking any medications, herbal supplements or other substances (including smoking) that are known to be strong inhibitors or moderate/strong inducers or sensitive substrates of CYP1A2, within less than 5 half-lives, prior to first dose of study drug. Any exception should be discussed with the Coordinating Investigator. For clarity, vaping (use of e-cigarettes) is not considered smoking.
  18. Significant cardiac dysfunction defined as myocardial infarction within 12 months of first dose of study drug, (NYHA) Class III or IV heart failure, uncontrolled dysrhythmias, or poorly controlled angina.
  19. Currently taking drugs that are documented, in the drug package insert, to have a risk of causing prolonged or torsades de pointes (TdP) within 5 half-lives, prior to first dose of study drug.

    Any exception should be discussed with the Coordinating Investigator.

  20. Personal or family history of serious ventricular arrhythmia, or QT interval corrected for heart rate (QTc) ≥470 ms.
  21. Any other prior or current medical condition, intercurrent illness, surgical history, physical or (ECG) findings, laboratory abnormalities, or extenuating circumstance (e.g. alcohol or drug addiction) that, in the Investigator's opinion, could jeopardize patient safety or interfere with the objectives of the study.
  22. Prior history of other than Acute myeloid leukemia (AML) or MDS, unless the patient has been free of the disease for 5 years or more prior to screening. Exceptions to the ≥5-year time limit include history of the following:

    • basal cell carcinoma of the skin
    • non- squamous cell carcinoma of the skin
    • carcinoma in situ of the cervix
    • carcinoma in situ of the breast
    • carcinoma in situ of the bladder
    • incidental histological finding of prostate cancer (Tumor/Node/Metastasis [TNM] stage of T1a or T1b).
  23. Pregnant or breast-feeding females
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Single-arm RVU120

    Drug: RVU120 (SEL120)

Interventions

  • RVU120 will be taken orally every other day (q.o.d). in a 21-day treatment cycle. Doses of RVU120 will be administered from day 1 to day 13 (total of 7 doses per cycle).

06

What researchers measure

Primary outcomes

  1. Erythroid Response (HI-E) Rate of Participants after Treatment with RVU120 (dose of 150 mg)

    The International Working Group (IWG) 2018 Hematologic Improvement Criteria for MDS will be used to define responders.

    Time frame: Response Assessment measured after 8 full Cycles of RVU120 administration. Each cycle is 21 days.

07

Study locations

25 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for May 2026, 20 months after the start.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 20 months is below that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Feb 6, 2024
StartActual
Sep 10, 2024
Primary completionEst.
May 2026
CompletionEst.
May 2027
Last update
May 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06243458
Lead sponsor
GCP-Service International West GmbH
Collaborators
Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group
Responsible party
Sponsor
First posted
Feb 6, 2024
Start date
Sep 10, 2024
Primary completion
May 2026 (estimated)
Completion
May 2027 (estimated)
Last update
May 22, 2025

Study contacts

Uwe Platzbecker, Prof.
principal investigator · Universitätsklinikum Leipzig
Lionel Adès, Prof.
principal investigator · Service d'hématologie seniors Hôpital Saint-Louis, Paris
Valeria Santini, Prof.
principal investigator · University of Careggi, Italy
Krzysztof Mądry, Dr.
principal investigator · Medical University of Warsaw
Diez Campelo, Dr.
principal investigator · University of Salamanca

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEL-120

Start the discussion